Bispecific Or Bifunctional, Or Multispecific Or Multifunctional, Antibody Or Fragment Thereof Patents (Class 424/136.1)
-
Patent number: 10188729Abstract: Methods of treating proliferative disorders are described. In particular, combination treatment with a GITR agonist and a PD-1 antagonist are provided.Type: GrantFiled: August 18, 2014Date of Patent: January 29, 2019Assignee: Merck Sharp & Dohme Corp.Inventors: Gu Danling, Amy M. Beebe
-
Patent number: 10191034Abstract: A method for assessing the risk of potential adverse effects for a human patient receiving a CD19×CD3 bispecific antibody is provided. The method comprises determining the total B count in the patient, and identifying a B cell number indicative of a patient at risk of potential adverse effects from the antibody. The method further provides a dosing schedule for administering the antibody to the patient identified as at risk of potential adverse effects. Also provided is a pharmaceutical package or kit comprising a first dose and a second dose, and optionally a third dose, of the CD19×CD3 bispecific antibody as defined in the methods/dosage regimen of the disclosure.Type: GrantFiled: April 30, 2012Date of Patent: January 29, 2019Assignee: AMGEN RESEARCH (MUNICH) GMBHInventor: Dirk Nagorsen
-
Patent number: 10168339Abstract: It is an object of the present invention to provide a marker substance capable of accurately determining a risk of developing metabolic syndrome in vivo. That is, the present invention provides the followings: a marker peptide for determining the risk of developing the metabolic syndrome; an antibody or an aptamer bound to the marker peptide for determining the risk of developing the metabolic syndrome; a microarray in which the antibody or the aptamer bound to the marker peptide for determining the risk of developing the metabolic syndrome has been immobilized on a carrier; a method for determining the risk of developing the metabolic syndrome, comprising measuring an amount or the presence or absence of the marker peptide for determining the risk of developing the metabolic syndrome in a biological sample collected from a subject; and a kit for determining the risk of developing the metabolic syndrome, comprising the antibody or the aptamer or comprising the microarray.Type: GrantFiled: December 27, 2012Date of Patent: January 1, 2019Assignee: LION CORPORATIONInventors: Chiyoko Uchiyama, Kei Kurita, Eriko Fukushima, Riichi Maki
-
Patent number: 10081679Abstract: The present invention provides compositions comprising anti-CEACAM1 antibodies, compositions comprising antibodies capable of inhibiting or blocking the interaction between PD-1 and its ligands, and methods for their combined use in treating cancer.Type: GrantFiled: November 25, 2014Date of Patent: September 25, 2018Assignee: CCAM BIOTHERAPEUTICS LTD.Inventors: Tehila Ben-Moshe, Yair Sapir, Ilana Mandel, Edna Meilin
-
Patent number: 10077315Abstract: A bispecific antibody specifically binding to the two targets human CD3? and human BCMA, wherein the variable domains of one antibody portion are replaced by each other, and characterized in that the binding of said antibody is not reduced by APRIL and not reduced by BAFF, said antibody does not alter APRIL-dependent NF-?B activation, BAFF-dependent NF-?B activation, and does not alter NF-?B activation without BAFF and APRIL is useful as a therapeutic agent.Type: GrantFiled: February 5, 2014Date of Patent: September 18, 2018Assignee: ENGMAB SÀRLInventors: Minh Diem Vu, Klaus Strein, Ekkehard Moessner, Ralf Hosse, Oliver Ast, Anne Freimoser-Grundschober, Marina Bacac, Tanja Fauti, Christian Klein, Pablo Umana, Samuel Moser
-
Patent number: 10072081Abstract: The disclosure relates to a protein composed of a first polypeptide or polypeptide domain having a first specific binding activity for Cytotoxic T-lymphocyte Antigen 4 (CTLA-4) expressed on a T-cell cell surface and a second specific binding activity for Glucose Transporter 2 (GLUT2) or an extracellular ectodomain thereof expressed on a pancreatic ?-cell surface, wherein binding of the first polypeptide or polypeptide domain to CTLA-4 induces a CTLA-4 specific agonist response in the T-cell, and binding of the second polypeptide or polypeptide domain to GLUT2 or an ectodomain thereof does not inhibit GLUT2 glucose transporter function, wherein said agonist response in the T-cell induces a response that reduces immunoreactivity against pancreatic ?-cells.Type: GrantFiled: November 17, 2015Date of Patent: September 11, 2018Assignee: The Board of Trustees of the University of IllinoisInventors: Bellur S. Prabhakar, Chenthamarakshan Vasu, Palash Bhattacharya
-
Patent number: 10072098Abstract: Polypeptides are provided that are capable of significantly inhibiting and/or neutralizing P aeruginosa. The polypeptides comprise two or more immunoglobulin single variable domains that are directed against the PcrV protein of P. aeruginosa, wherein the “first” immunoglobulin single variable domain and the “second” immunoglobulin single variable domain have different paratopes.Type: GrantFiled: March 4, 2013Date of Patent: September 11, 2018Assignee: Ablynx N.V.Inventors: Evelyn De Tavernier, Ann Union, Bruno Dombrecht, Guy Hermans, Erika Morizzo
-
Patent number: 10047163Abstract: Provided are novel multispecific antibody constructs and multispecific antibody drug conjugates (ADCs), and methods of using such antibodies and ADCs to treat cancer. IgG-like bispecific antibodies have different binding specificities on each arm of the antibody. They are similar in structure to monospecific IgGs in that they contain two heavy chains with VH, CH1, CH2 and CH3 regions, and two light chains with VL and CL regions.Type: GrantFiled: February 7, 2014Date of Patent: August 14, 2018Assignee: AbbVie Stemcentrx LLCInventor: David Liu
-
Patent number: 10000569Abstract: An anti-EGFR/anti-HER3 antibody or antigen binding fragment thereof, and a method of preventing and/or treating a cancer using the same.Type: GrantFiled: April 22, 2015Date of Patent: June 19, 2018Assignee: SAMSUNG ELECTRONICS CO., LTD.Inventors: Kwang Ho Cheong, Jae Woong Hwang, Seung Hyun Lee, Powei Lin, Mi Young Cho
-
Patent number: 9988611Abstract: The invention provides bispecific fusion proteins that inhibit activation of complement pathway and vascular endothelial growth factor (VEGF) pathway and methods for using these fusion proteins.Type: GrantFiled: November 30, 2012Date of Patent: June 5, 2018Assignees: AP Biosciences, Inc., Innovent Biologics, Inc.Inventors: Jeng-Horng Her, Huang-Tsu Chen
-
Patent number: 9970849Abstract: An improved method for the preparation of target specific surfaces and uses thereof is described. In particular, the surfaces are bound to mono-specific tetrameric antibody complexes prior to their addition to a sample containing target entities and separating them from non-target entities.Type: GrantFiled: January 21, 2015Date of Patent: May 15, 2018Assignee: StemCell Technologies Inc.Inventor: Andy Isamu Kokaji
-
Patent number: 9958461Abstract: The present invention relates to methods and kits for detecting the interaction between a first membrane protein and a second protein in mammalian cells as well as to identify molecules that can disrupt protein to protein interactions. The invention relies on the functional reconstitution of an active human ubiquitin by two inactive fragments upon the interaction of two proteins attached through a linker to the inactive fragments. The reconstituted ubiquitin is then cleaved by human ubiquitin proteases resulting in the release of an artificial transcription factor, which in turn activates a reporter gene transcription. Activation of the reporter gene is indicative of the interaction between the two proteins.Type: GrantFiled: June 10, 2014Date of Patent: May 1, 2018Assignee: THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTOInventors: Igor Stagljar, Julia Petschnigg, Bella Groisman
-
Patent number: 9951118Abstract: The HIV-specific cytotoxic T lymphocyte (CTL) response is a critical component in controlling HIV replication and is an important part of the ultimate failure to eradicate the virus. Disclosed herein are methods for genetically enhancing the HIV-specific CTL response to allow long-term viral suppression or viral clearance. Human hematopoietic stem cells (HSCs) were genetically modified such that they differentiate into mature CTLs that will kill HIV infected cells. As disclosed herein, the functional effector cells are not human leukocyte antigen (HLA)-restricted. As disclosed herein, stem cells are transduced with non-HLA restricted chimeric antigen receptors (CARs) that allow the recognition of HIV or HIV-infected cells when expressed by a CTL. These CARs are hybrid molecules that contain an extracellular HIV recognition domain and an intracellular TCR-zeta signaling domain. The CTL response may be enhanced through the targeting of T cell inhibitory receptors.Type: GrantFiled: August 1, 2014Date of Patent: April 24, 2018Assignee: The Regents of the University of CaliforniaInventors: Scott G. Kitchen, Jerome A. Zack, Otto O. Yang, Irvin Chen, Masakazu Kamata
-
Patent number: 9944709Abstract: The present invention relates to Chimeric Antigen Receptors (CAR) that are recombinant chimeric proteins able to redirect immune cell specificity and reactivity toward selected membrane antigens, and more particularly in which extracellular ligand binding is a scFV derived from a CD123 monoclonal antibody, conferring specific immunity against CD123 positive cells. The engineered immune cells endowed with such CARs are particularly suited for treating lymphomas and leukemia.Type: GrantFiled: March 19, 2015Date of Patent: April 17, 2018Assignee: CELLECTISInventor: Roman Galetto
-
Patent number: 9915665Abstract: System and methods are disclosed for identifying and isolating antibodies with specific affinity with an antigen of interest. Multiple DNA libraries encoding antibodies or their fragments are designed such that the encoded antibodies from different libraries are tagged differently. These libraries may be transformed into yeast cells. The variants of the antibodies are displayed on the surface of the yeast cells and flow cytometry may be used to sort the cells based on antigen affinity and the different tags on the antibodies. By allowing multiple libraries to be screened simultaneously, the disclosed methods help improve the efficiency of affinity.Type: GrantFiled: December 27, 2013Date of Patent: March 13, 2018Assignee: ABBVIE INC.Inventors: Lorenzo Benatuil, Jennifer Perez, Chung-Ming Hsieh
-
Patent number: 9914776Abstract: The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.Type: GrantFiled: August 3, 2015Date of Patent: March 13, 2018Assignee: Hoffmann-La Roche Inc.Inventors: Oliver Ast, Marina Bacac, Sabine Imhof-Jung, Christiane Jaeger, Christian Klein, Stefan Klostermann, Michael Molhoj, Joerg Thomas Regula, Wolfgang Schaefer, Pablo Umana
-
Patent number: 9896513Abstract: The application discloses a combination of two monospecific TFPI antibodies, wherein one antibody is capable of specifically binding TFPI (1-181) and the other antibody is capable of specifically binding TFPI (182-276), as well as bispecific anti-TFPI antibodies derived from two such monospecific antibodies. Both the combination of the two monospecific antibodies and the bispecific antibody strongly enhance thrombin generation by neutralising full length TFPI?, even where the concentration of TFPI is abnormally elevated.Type: GrantFiled: March 14, 2014Date of Patent: February 20, 2018Assignee: Novo Nordisk A/SInventors: Berit O. Krogh, Mikael Kofod-Hansen, Ida Hilden, Helle H. Petersen, Lars C. Petersen, Jens Breinholt
-
Patent number: 9884117Abstract: Stable formulations are provided that contain immunoglobulin single variable domains at a high concentration. The formulations are useful as pharmaceutical formulation and suitable for subcutaneous administration. The formulations can be transported and stored under various stress conditions. The invention further relates to containers and pharmaceutical units comprising such formulations and to methods for preparing and prophylactic and therapeutic uses of the formulations and pharmaceutical units of the invention.Type: GrantFiled: September 3, 2010Date of Patent: February 6, 2018Assignee: Ablynx N.V.Inventors: Ann Brige, Christine Labeur, Marc Jozef Lauwereys
-
Patent number: 9885711Abstract: The present invention provides polypeptide binding agents, e.g. antibodies, that exhibit the ability to kinetically modulate the binding and signaling of biological signaling complexes, e.g., receptor-ligand complexes; methods of identifying such polypeptide binding agents, methods of making such polypeptide binding agents, compositions comprising such polypeptide binding agents, and methods of using such polypeptide binding agents.Type: GrantFiled: September 24, 2010Date of Patent: February 6, 2018Assignee: XOMA Technology Ltd.Inventors: Mark L. White, Marina Roell, John Corbin, Robert Bauer, Daniel Bedinger
-
Patent number: 9884921Abstract: Bispecific heterodimeric diabody molecules and uses thereof in the treatment of cancer. The bispecific heterodimeric diabody molecules comprise two polypeptide chains that associate to form two epitope binding sites recognizing the P-cadherin tumor cell associated antigen and the CD3 T cell antigen.Type: GrantFiled: June 26, 2015Date of Patent: February 6, 2018Assignee: Pfizer Inc.Inventors: Chad Michael May, Adam Reid Root, William A. Brady, Lioudmila Gennadievna Tchistiakova, Lidia Mosyak, Laird Bloom, Paul A. Moore, Leslie S. Johnson
-
Patent number: 9856319Abstract: Engineered monovalent binding proteins that bind to one or more ligands (such as an antigen) via one binding domain are provided, along with methods of making and uses in the prevention, diagnosis, and/or treatment of disease.Type: GrantFiled: December 27, 2013Date of Patent: January 2, 2018Assignee: ABBVIE INC.Inventors: Tariq Ghayur, Jijie Gu
-
Patent number: 9828434Abstract: The present invention comprises human monoclonal antibodies that bind to PD-L1 (also known as programmed death ligand 1 or B7H1). Binding of the invented antibody to PD-L1 inhibits binding to its receptor, PD1 (programmed death 1), and ligand-mediated activities and can be used to treat cancer and chronic viral infections.Type: GrantFiled: October 4, 2013Date of Patent: November 28, 2017Assignee: Dana-Farber Cancer Institute, Inc.Inventors: Wayne A. Marasco, Jianhua Sui
-
Patent number: 9783611Abstract: The invention relates to specific anti-HER3 antibodies, that bind to the beta-hairpin of HER3, their preparation and use as medicament.Type: GrantFiled: May 12, 2015Date of Patent: October 10, 2017Assignee: Hoffman-La Roche Inc.Inventors: Birgit Bossenmaier, Richard Buick, Michael Gerg, Frank Kroner, Gerhard Niederfellner, Carmen Peess, Michael Schraeml
-
Patent number: 9783609Abstract: The present invention relates to a substance specific to human PD-1 comprising a part that recognizes human PD-1, a part that recognizes a membrane protein in cell membrane of human PD-1-expressing cells, and linkers. Since the substance specific to human PD-1 selectively can recognize human PD-1 and a membrane protein on cell membrane of human PD-1-expressing cells and can transmit inhibitory signal of human PD-1, it is useful for therapy and/or prevention of diseases caused by immunopathy.Type: GrantFiled: December 29, 2014Date of Patent: October 10, 2017Assignees: ONO PHARMACEUTICAL CO., LTD.Inventors: Tasuku Honjo, Shiro Shibayama, Kazuhiko Takeda, Masayoshi Matsuo, Takao Yoshida, Masakazu Miyamoto
-
Patent number: 9782410Abstract: The disclosed subject matter provides methods using and kits comprising a compound of formula (I) or a hydrate, a solvate, or a pharmaceutically acceptable salt thereof. The disclosed subject matter further provides a method of treating one or more symptoms of cancer comprising administering to a subject in need thereof a compound of formula (I) and a process for preparing such.Type: GrantFiled: June 9, 2016Date of Patent: October 10, 2017Assignee: REXAHN PHARMACEUTICALS, INC.Inventors: Young B. Lee, Deog J. Kim, Reza Mazhari, Godefridus J. Peters, Dzjemma Sarkisjan
-
Patent number: 9765157Abstract: The present invention provides a bispecific antibody construct comprising a first human binding domain which binds to human CDH19 on the surface of a target cell and a second binding domain which binds a human CD3 on the surface of a T cell. Moreover, the invention provides a polynucleotide encoding the antibody construct, a vector comprising the polynucleotide and a host cell transformed or transfected with the polynucleotide or vector. Furthermore, the invention provides a process for the production of the antibody construct of the invention, a medical use of the antibody construct in the treatment of melanoma, and a kit comprising the antibody construct.Type: GrantFiled: July 31, 2015Date of Patent: September 19, 2017Assignee: AMGEN RESEARCH (MUNICH) GMBHInventors: Shouhua Xiao, Zheng Pan, Dineli Wickramasinghe, Peter Kufer, Patrick Hoffmann, Tobias Raum, Ralf Lutterbüse, Elisabeth Nahrwold, Claudia Blumel
-
Patent number: 9758805Abstract: The invention provides means and methods for producing one or more Ig-like molecules in a single host cell. Novel CH3 mutations enabling the production of monospecific and/or bispecific Ig-like molecules of interest are also provided.Type: GrantFiled: December 18, 2015Date of Patent: September 12, 2017Assignee: Merus N.V.Inventors: Cornelis Adriaan De Kruif, Linda Johanna Aleida Hendriks, Ton Logtenberg
-
Patent number: 9745381Abstract: Certain embodiments are directed to a bispecific immunoglobulin that is capable of binding cell surface molecules on a target cell, such as cancer cells, and cell surface molecules on immune effector cell, such as cytotoxic T lymphocytes, resulting in the targeted killing of target cells. In certain aspects a Bif is a polypeptide comprising a first target binding domain that specifically binds a cancer cell, a second effector binding domain that specifically binds an immunologic effector, and an immunoglobulin constant region linker operatively coupling the first and second binding domain.Type: GrantFiled: May 18, 2013Date of Patent: August 29, 2017Assignee: Scott & White Healthcare (SWH)Inventors: Jen-Sing Liu, Shu-Ru Kuo
-
Patent number: 9738728Abstract: The present invention relates to novel humanized anti-IL-4 and IL-13 antibodies and fragments thereof and novel bispecific antibodies and fragments thereof that specifically bind to IL-4 and IL-13. The invention also includes uses of the antibodies to treat or prevent IL-4 and/or IL-13 mediated diseases or disorders, including allergic asthma and dermatitis.Type: GrantFiled: March 11, 2013Date of Patent: August 22, 2017Assignee: SanofiInventors: Ercole Rao, Vincent Mikol, Danxi Li, Jochen Kruip, Matthew Davison
-
Patent number: 9732162Abstract: The present invention relates to novel humanized anti-IL-4 and IL-13 antibodies and fragments thereof and novel bispecific antibodies and fragments thereof that specifically bind to IL-4 and IL-13. The invention also includes uses of the antibodies to treat or prevent IL-4 and/or IL-13 mediated diseases or disorders, including allergic asthma and dermatitis.Type: GrantFiled: March 15, 2013Date of Patent: August 15, 2017Assignee: SanofiInventors: Ercole Rao, Vincent Mikol, Danxi Li, Jochen Kruip, Matthew Davison
-
Patent number: 9725520Abstract: Isolated or recombinant anti-HER3 monoclonal antibodies are provided. In some cases, antibodies of the embodiments can be used for the detection, diagnosis and/or therapeutic treatment of human diseases, such as cancer.Type: GrantFiled: March 13, 2014Date of Patent: August 8, 2017Assignee: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEMInventors: Ningyan Zhang, Zhiqiang An
-
Patent number: 9718893Abstract: The present invention relates to a bispecific antibody molecule, as well as a method for producing the same, its use and a nucleic acid molecule encoding the bispecific antibody molecule. The invention in particular provides an antibody molecule that is capable of mediating target cell restricted activation of immune cells.Type: GrantFiled: November 12, 2012Date of Patent: August 1, 2017Assignee: SYNIMMUNE GMBHInventors: Gundram Jung, Michael Durben, Ludger Grosse-Hovest
-
Patent number: 9688763Abstract: The present invention relates to polypeptides directed against or specifically binding to chemokine receptor CXCR2 and in particular to polypeptides capable of modulating signal transduction from CXCR2. The invention also relates to nucleic acids, vectors and host cells capable of expressing the polypeptides of the invention, pharmaceutical compositions comprising the polypeptides and uses of said polypeptides and compositions for treatment of diseases involving aberrant functioning of CXCR2.Type: GrantFiled: June 26, 2015Date of Patent: June 27, 2017Assignee: Novartis AGInventors: Zarin Brown, Michelle Bradley, Steven John Charlton, Gino Anselmus Van Heeke, Karen Cromie, Bruno Dombrecht, Soren Steffensen, Judith Baumeister, Marie-Paule Bouche, Carlo Boutton, Marie-Ange Buyse, Veerle Snoeck, Stephanie Staelens
-
Patent number: 9657107Abstract: Isolated monoclonal antibodies which bind to human c-Met, the hepatocyte growth factor receptor, and related antibody-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies are also disclosed.Type: GrantFiled: May 26, 2015Date of Patent: May 23, 2017Assignee: GENMAB A/SInventors: Joost J. Neijssen, Bart De Goeij, Edward Norbert Van Den Brink, Aran Frank Labrijn, Rene Hoet, Janine Schuurman, Paul Parren, Jan Van De Winkel
-
Patent number: 9637541Abstract: An anti-c-Met/anti-Ang2 bispecific antibody, a composition including the anti-c-Met/anti-Ang2 bispecific antibody, and a method of preventing and/or treating a cancer in a subject including administering the anti-c-Met/anti-Ang2 bispecific antibody to the subject.Type: GrantFiled: December 1, 2014Date of Patent: May 2, 2017Assignee: SAMSUNG ELECTRONICS CO., LTD.Inventors: Hyung-Chan Kim, Kyung Eun Kim, Yoon Sook Lee, Mi Young Cho
-
Patent number: 9623117Abstract: The present invention provides methods and reagents for directing the selective targeting and entry of bacterial toxins to mammalian cells. Methods include the step of contacting a cell with a bacterial toxin or toxic bioactive fragment thereof associated with an antibody or ligand that is specific to a target on the cell, wherein the antibody or ligand selectively binds the target on the cell and the bacterial toxin or fragment thereof is internalized and enters the cell. The invention further encompasses compositions and kits to carry out the methods.Type: GrantFiled: March 30, 2012Date of Patent: April 18, 2017Assignee: Wisconsin Alumni Research FoundationInventors: Edwin Raymond Chapman, Felix Leejia Yeh
-
Patent number: 9624291Abstract: An antibody is provided. The antibody comprises an Fc region and a Fab region, wherein: (i) the Fc region comprises two non-identical heavy chains, wherein at least one of the two non-identical heavy chains comprises an amino acid modification so as to form complementation between the two non-identical heavy chains thereby increasing the probability of forming heterodimers of the non-identical heavy chains and decreasing the probability of forming homodimers of identical heavy chains; and (ii) the Fab region comprises a first covalent link between a first heavy chain and a first light chain of the Fab region and a second covalent link between a second heavy chain and a second light chain of said Fab region, wherein a position of the first covalent link relative to the first heavy chain is different to a position of the second covalent link relative to the second heavy chain.Type: GrantFiled: March 15, 2012Date of Patent: April 18, 2017Assignee: Ramot at Tel-Aviv University Ltd.Inventors: Itai Benhar, Lilach Vaks
-
Patent number: 9611325Abstract: The present invention provides a bispecific antibody. The bispecific antibody provided by the present invention comprises a single-chain unit and a monovalent unit, wherein the single-chain unit has a specific binding capability against a surface antigen CD3 of an immune cell; the monovalent unit has a specific binding capability against a surface antigen HER2 of a tumor cell; the single-chain unit comprises a single-chain variable fragment ScFv fused with an Fc fragment; and the monovalent unit comprises a light chain and heavy chain pair. The present invention also provides a preparation method of the bispecific antibody and pharmaceutical use of these antibodies.Type: GrantFiled: July 20, 2015Date of Patent: April 4, 2017Assignee: Wuhan YZY Biopharma Co., Ltd.Inventors: Pengfei Zhou, Jing Zhang, Lingli Hu, Rui Wang, Xiang Zhou, Kesu Fan
-
Patent number: 9605242Abstract: The invention relates to a method performed ex vivo for removal of tumor cells from intraoperatively collected blood salvage, to antibodies and scaffold proteins which mimic antibodies for use in said ex vivo method, to the use of said ex vivo method for removal of tumor cells from intraoperatively collected blood salvage followed by reintroducing the so obtained purified blood salvage or of concentrates of erythrocytes purified by said method to a patient from whom said intra-operatively collected blood was obtained, as well as to blood salvage or a concentrate of erythrocytes, both obtainable by said method for reinfusion to said patient.Type: GrantFiled: October 4, 2012Date of Patent: March 28, 2017Assignee: Horst LindhoferInventors: Horst Lindhofer, Michael Stroehlein, Markus Heiss
-
Patent number: 9605076Abstract: Methods are provided to manipulate phagocytosis of cancer cells, including e.g. leukemias, solid tumors including carcinomas, etc.Type: GrantFiled: February 26, 2016Date of Patent: March 28, 2017Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Siddhartha Jaiswal, Irving L. Weissman, Ravindra Majeti, Mark P. Chao
-
Patent number: 9587022Abstract: Disclosed herein are glycan-modified anti-CD4 monoclonal antibodies with N-linked glycans attached to the variable region. Expression vectors and cell lines useful for the production of such antibodies, and use of such antibodies for HIV prevention and therapy are also disclosed.Type: GrantFiled: December 18, 2013Date of Patent: March 7, 2017Assignee: THE ROCKEFELLER UNIVERSITYInventors: Ruijiang Song, David D. Ho
-
Patent number: 9587012Abstract: In various embodiments, the present invention relates generally to using bispecific antibodies in the prevention and treatment of HIV.Type: GrantFiled: December 2, 2014Date of Patent: March 7, 2017Assignee: AARON DIAMOND AIDS RESEARCH CENTERInventors: David D. Ho, Yaoxing Huang, Jian Yu
-
Patent number: 9580509Abstract: The disclosure generally provides proteins that bind two epitopes (e.g., a first and a second epitope) and that are bivalent for binding to each of the first and second epitopes. The disclosure also provides compositions comprising such proteins, nucleic acid molecules encoding such proteins and methods of making and using such proteins.Type: GrantFiled: November 6, 2012Date of Patent: February 28, 2017Assignee: MedImmune, LLCInventors: Nazzareno Dimasi, Ryan Fleming, Binyam Bezabeh, Changshou Gao, Antonio Digiandomenico, Paul Warrener, Charles Stover, Bret Sellman, Mladen Tomich, Reena Varkey, Partha S. Chowdhury, Ralph Minter, Sandrine Guillard, Steven Rust, Vignesh Venkatraman
-
Patent number: 9562092Abstract: The present disclosure provides antibodies that bind complement C1s protein; and nucleic acid molecules that encode such antibodies. The present disclosure also provides compositions comprising such antibodies, and methods to produce and use such antibodies, nucleic acid molecules, and compositions.Type: GrantFiled: November 4, 2015Date of Patent: February 7, 2017Assignee: True North Therapeutics, Inc.Inventors: Peter Van Vlasselaer, Graham Parry, Nancy E. Stagliano, Sandip Panicker
-
Patent number: 9527920Abstract: The present invention relates to new monoclonal antibodies and fragments of these antibodies, which have dual specificity and high affinity for N-acetyl GM3 and N-glycolyl GM3 and do not recognize other gangliosides. In another aspect, the present invention relates to the use of these antibodies and their fragments in the therapy of tumors characterized by a significant expression of any of the two antigens recognized by these antibodies, or a mixed expression of both antigens. Likewise, the invention relates to the use of these antibodies in the diagnosis of tumors expressing at least one of the two variants of the GM3 ganglioside.Type: GrantFiled: February 21, 2013Date of Patent: December 27, 2016Assignee: CENTRO DE IMMUNOLOGIA MOLECULARInventors: Ernesto Moreno Frias, Gertrudis Rojas Dorantes, Ana Victoria Casadesus Pazos
-
Patent number: 9522956Abstract: The invention relates to the combined use of anti-EGFR antibodies and anti-Her2 antibodies for the treatment of cancer, especially suitable for cancer expressing high levels of the EGFR type and low levels of HER2. The invention refers in particular monoclonal antibody “trastuzumab” (HERCEPTIN®) directed against the HER2 receptors the efficacy of which can be significantly increased in vivo when combined with monoclonal antibody “matuzumab” (hmAB 425, EMD 72000) directed against EGF receptors. The combination treatment is suitable for patients suffering from cancer having said receptor profile, preferably pancreatic cancer.Type: GrantFiled: November 10, 2014Date of Patent: December 20, 2016Assignee: L'Institut National de la Sante et de la Recherche MedicaleInventors: Stephen D. Gillies, David Azria, Christel Larbouret, André Pelegrin
-
Patent number: 9470683Abstract: A method of determining aggregates of a macromolecule monomer in a fluid containing the macromolecule, comprises the steps of: contacting a sample of the fluid with a sensing surface of an interaction analysis sensor, wherein the sensing surface is capable of specific binding interaction with the macromolecule, determining at least one kinetic parameter for the interaction of the fluid sample with the sensing surface, comparing the determined kinetic parameter or parameters with that or those determined for at least one fluid sample having a known fraction or fractions of aggregates of the macromolecule, and determining therefrom the fraction of macromolecule in the sample that is in the form of aggregate or aggregates.Type: GrantFiled: January 27, 2011Date of Patent: October 18, 2016Assignee: GE HEALTHCARE BIO-SCIENCES ABInventors: Stefan Lofas, Bjorn Persson
-
Patent number: 9464136Abstract: The present invention features antibody-based constructs that include a combination of two or more of a tetrameric antibody, a single chain antibody, a diabody, a triabody, another immunoglobulin-based moiety, as described herein, or biologically active variants thereof.Type: GrantFiled: August 20, 2011Date of Patent: October 11, 2016Assignee: Massachusetts Institute of TechnologyInventors: Karl Dane Wittrup, Jamie B. Spangler, Benjamin E. Epstein, Brian L. Ross
-
Patent number: 9416197Abstract: The present invention concerns compositions and methods of use of bispecific antibodies comprising at least one anti-TNF-? antibody or antigen-binding fragment thereof and at least one anti-IL-6 antibody or antigen-binding fragment thereof. Preferably, the bispecific antibody is in the form of a DNL® complex. The anti-TNF-? or anti-IL-6 antibodies may comprise specific CDR sequences disclosed herein. The compositions and methods are of use to treat autoimmune disease, immune system dysfunction or inflammatory disease, as disclosed herein.Type: GrantFiled: October 28, 2014Date of Patent: August 16, 2016Assignee: IBC Pharmaceuticals, Inc.Inventors: David M. Goldenberg, Rongxiu Li, Chien-Hsing Chang
-
Patent number: 9416183Abstract: The present invention relates to blocking, inhibiting, reduceing, antagonizing or neutralizing the activity of IL-17A and IL-17F. IL-17A and IL-17F are cytokines that are involved in inflammatory processes and human disease. The present invention includes antibodies that bind both IL-17A and IL-17F, hybridomas that produce the antibodies, and methods of using the same in inflammation.Type: GrantFiled: September 23, 2014Date of Patent: August 16, 2016Assignee: ZymoGenetics, Inc.Inventors: Stephen R. Jaspers, Scott R. Presnell, Monica J. Huber